In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
This content type () is not supported by this display view

Young Investigator Awards and ACCA Research Prize

Award sessions at Acute Cardiovascular Care

Congratulations to the winners:

  • Young Investigator Award: Jacob Gammelgaard Schultz (Skejby, Denmark)
  • ACCA Research Prize: Martin Frydland (Copenhagen, Denmark)

Young Investigator Awards

The Young Investigator Award (YIA) competition is designed for presenters who are 35 or under.

YIA Finalists presented their research and a panel of experts who determined the winner.  All YIA finalists will benefit from a free registration to Acute Cardiovascular Care 2018 and will have the opportunity to submit a paper for FAST TRACK review & immediate publication in the EHJ-ACVC.

Congratulations to the winner - Dr. Jacob Gammelgaard Schultz (Skejby, Denmark)

Gammelgaard-Schultz-Jacob-2018.jpgJacob Schultz graduated from Aarhus University Medical School in 2015 and has since been enrolled as a PhD fellow at the Department of Cardiology, Aarhus University Hospital, Denmark.

Jacob Schultz was however already active in research during medical school and has been involved in both basic, experimental and clinical studies.

The primary focus of Jacob Schultz is now acute pulmonary embolism. The aim of his PhD is to evaluate novel pharmacological and catheter-based therapies in a porcine model of acute pulmonary embolism.

‘’NO-sGC-cGMP pathway stimulation lowers pulmonary vascular resistance in a porcine model of acute pulmonary embolism’’

Inhaled NO, riociguat, and sildenafil reduce pulmonary vascular resistance in a porcine model of acute pulmonary embolism without lowering of systemic blood pressure.


Dr. Jasper Boeddinghaus (Basel, Switzerland)

Boeddinghaus-Jasper-2018.jpgI graduated from medical school at the University Hospital Hamburg-Eppendorf in 2014. As a doctoral student (Institute of Experimental Pharmacology and Toxicology, Prof. Thomas Eschenhagen) I developed an external pacing-system for continuous electrical stimulation of Engineered Heart Tissues

In 2015, I joined the research group of Prof. Christian Mueller at the Cardiovascular Research Institute Basel (CRIB) and started my residency in internal medicine. Since then, my research activities focus on biomarker- and outcome-research and specifically on the development and refinements of algorithms using high-sensitivity cardiac troponin assays for triage of patients with suspected myocardial infarction presenting to the emergency department.

‘’Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction’’

We prospectively investigated the impact of age on the performance of the ESC 0/1h-algorithms in a large multicentre diagnostic study using central adjudication. In a second step, specific alternative cut-off concentrations for older patients derived in this multicentre study were externally validated in two additional diagnostic studies. 

Dr. Benedikt Schrage (Hamburg, Germany)


Dr. Schrage is a fourth year cardiology resident at the University Heart Centre Hamburg.

In his clinical practice, he is mainly involved in the care of patients with acute and chronic heart failure. This is also the main area of his research, with a special emphasis on cardiogenic shock and its treatment using mechanical circulatory support systems.

‘’Percutaneous unloading of the left ventricle during extracorporeal membrane oxygenation in cardiogenic shock: ongoing experience from a high-volume centre’’

Presentation of the ongoing experience with the “ECMELLA” approach – Addition of an Impella on top of a VA-ECMO for left ventricular unloading during cardiogenic shock.

Dr. Krishnaraj Rathod (London, United Kingdom)

Rathod-Krishnaraj-2018.jpgI am currently a Cardiology SpR at Barts Heart Centre and PhD student at Queen Mary University of London.

This PhD has been funded by a highly prestigious NIHR Doctoral Research Fellowship.
I am currently conducting a number of clinical trials including a phase II clinical trial (NITRATE-OCT) involving 246 patients, investigating the use of dietary nitrate in patients with stable angina, particularly looking at its effects on restenosis and platelet reactivity. I also have an interest in investigating outcomes after percutaneous coronary intervention in both stable and ACS patients.

In addition, I am currently undertaking a distance learning MSc in Clinical Trials at the London School of Hygiene and Tropical Medicine and I am a sub-editor for both the BCS and BCIS.

‘’Complete revascularisation versus culprit only lesion intervention in ACS patients with multi-vessel disease: Incidence and outcomes from The London Heart Attack Group’’

This abstract investigates the role of complete revascularisation in patients with multivessel disease in NSTEMI. This is the largest observation study to date and has found that patient with complete revascularisation have lower long term mortality rates compared to culprit only revascularisation.

Dr. Nils Sörensen (Hamburg, Germany)

Sörensen-Nils-2018.jpgNils Arne Sörensen studied Medicine at the University of Hamburg and graduated 2013. He started his training in Cardiology at the Department of General and Interventional Cardiology at the University Heart Center Hamburg in 2014.

He is study coordinator for the Biomarkers in Cardiac Care (BACC) study with a special research interest in the diagnostic and prognostic value of biomarkers in acute coronary syndrome.

‘’Analytical variation in high-sensitivity troponin I measurements - comparison of live and batched analyses’’

There is a considerable analytical difference between live and batched analyses of high-sensitive troponin I with the highest impact at very low troponin concentrations. These results have potential influence on current ESC Guidelines, which recommend the application of very low troponin levels for early rule-out protocols.

Dr. Claus Kjær Pedersen (Aahrus, Denmark)

Kjær-Pedersen-Claus-2018.jpgClaus Kjær Pedersen, MD., Resident in Cardiology, PhD fellow at the Department of Cardiology, Aarhus University Hospital, Denmark. Member of a research group, which for more than a decade has been involved in research within prehospital diagnostics, treatment and management of cardiac patients, in particularly patients suspected of acute myocardial infarction.

Currently running a randomized controlled trial (the AROMI trial), evaluating the combination of prehospital copeptin and in-hospital hs-cTnT for early rule-out of AMI.

‘’Copeptin and troponin for rule-out of AMI reduces length of stay (the AROMI study)’’

The first results from the randomized controlled AROMI-trial shows that accelerated rule out of acute myocardial infarction, using copeptin and high sensitivity troponin t, reduces hospital length of stay.

ACCA Research Prize

ACCA Research Prize: scientists and clinicians are invited to submit their un-published research in the area of acute cardiovascular care with a focus on quality of care research, clinical outcomes research and translational research applied to the development of novel therapeutic, diagnostic and logistical strategies to improve patient care and long-term outcomes.

Congratulation to the winner - Martin Frydland (Copenhagen, Denmark)

frydland-martin-2018.jpgI graduated from Aarhus University, Denmark in 2012.

My interest in acute cardiology began during medical school where I worked with a pre-conditioning/myocardial infarction porcine model. After graduation, I focused on training in cardiology, working in the clinic for 3 years with acute cardiovascular diseases. During my clinical work, my interest in acute cardiology increased and I have written papers on cardiac arrest and cardiogenic shock. This spring, I will turn in my phd-thesis on biomarkers in cardiogenic shock at Copenhagen University with professor Christian Hassager as my primary supervisor.

Hereafter, I will continue my specialist training in cardiology.

‘’Biomarkers reflecting cardiovascular stress, neuroendocrine response, and inflammation are predictive of late cardiogenic shock in patients with suspected ST-elevation myocardial infarction’’

In this study, we assessed the predictive value of biomarker plasma level on late cardiogenic shock development in >2.000 consecutive patients admitted for acute coronary angiography with suspected STEMI.

Marek Gierlotka (Zabrze, Poland)

Gierlotka-Marek-2018.jpgHe studied medicine at the Medical University of Silesia. Affiliated to the 3rd Department of Cardiology in Silesian Centre for Heart Diseases in Zabrze as a Deputy Head for Intensive Cardiac Care and Acute Coronary Syndromes. Interventional cardiologist. Associate Professor. He specializes in the methodology and analysis of big registry data, both from epidemiological and clinical perspective. Since 2003, co-author and coordinator of the Polish Registry of Acute Coronary Syndromes PL-ACS, and since 2013 Co-Chair of the Scientific Board of the Nationwide Database of Acute Myocardial Infarction AMI-PL. Current President of Intensive Cardiac Care and Resuscitation Section of Polish Cardiac Society.

“12-month mortality after early and late resuscitated cardiac arrest in acute myocardial infarction”

Early resuscitated cardiac arrest is associated with lower mortality than late. However, adjusted effect of early and late resuscitated cardiac arrest on 12-month post-discharge mortality seems to be comparable.

Aleksandra Gombozhapova (Tomsk, Russia)

Gombozhapova-Aleksandra-2018.jpgAleksandra Gombozhapova studied Medicine at Siberian State Medical University (Tomsk, Russia), graduating in 2012.

Her training at clinical residency in cardiology was completed in the Cardiology Research Institute, Tomsk National Research Medical Center (TNRMC), in 2014. Currently, she is a cardiologist and research fellow at the Department of Cardiac Emergency, Cardiology Research Institute, TNRMC, and is completing her PhD thesis in cardiology.

Her research work is devoted to the role of cardiac macrophages in wound healing in patients with myocardial infarction (MI). In the course of performance of this work, a research protocol using macrophage biomarkers was suggested in order to study the cellular basis of cardiac remodeling in patients with acute MI.

‘’Cardiac macrophages in wound healing following myocardial infarction: from experiment to clinic’’

Our study translated experimental knowledge regarding macrophage subpopulations in post-infarction myocardial regeneration into clinical and supported diagnostic prospects for implementation of macrophage phenotyping in clinical practice. Identifying effective markers of different macrophage subsets in patients with MI might become the basis of a method to predict adverse cardiac remodeling and the first step in developing myocardial regeneration target therapy.

Idit Dobrecky (Haifa, Israel)

Dobrecky-Idit-2018.jpgDoctor Idit Dobrecky Mery, 48 years old, married with 4 children, graduated with honor in 1992 from Technion Institute Medical School.

He completed both residencies in Internal medicine and Cardiology in Carmel hospital in Haifa, Israel (both with honors).

Fellow in CT Cardiac imaging in Carmel hospital with Dr Tamar Gaspar and Prof Roberto Lang (Northwestern Chicago University)
Current Director of ICCU Bnai Zion Haifa Israel and senior lecturer in the Technion Haifa faculty of medecine.

‘’Hypoglycemic events during hospitalization in diabetic acute coronary syndrome patients treated with vildagliptin vs. guidelines based medical therapy’’

We studied Vildagliptin for improved glucose levels control in diabetic ACS patients with the caution of preventing hypoglycemia while intensifying the glucose control.
8 cases of hypoglycemia occurred in the control group in comparison to none in the Vildagliptin treated patients (t (45) =2.070, p<.001).